Addendum

Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31

Status
Status: Commission completed
Project no.
A21-103
Last updated

Report documents

  1. Addendum

    Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31

    published on
    Document type
    PDF document, 323 kB, EN, not accessible

Dossier assessment

Indication:

Adult patients with severe thrombocytopenia and chronic liver disease who are scheduled to undergo an invasive procedure

Result of dossier assessment:

Unchanged after addendum:

  • Moderate or high bleeding risk of the invasive procedure: proof of considerable added benefit.
  • Low bleeding risk of the invasive procedure: added benefit not proven.

Additional information

Federal Joint Committee (G-BA)

2021-09-16 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A21-103
Commission
Commission awarded on 10.08.2021 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-31
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form